|
|
|
|
|
|
|
|
|
|
Note: ovarian cancer patients were included in this phase 1 study but abstract gives limited information
Thursday, January 07, 2010
BJC - Abstract: Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
Note: ovarian cancer patients were included in this phase 1 study but abstract gives limited information
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.